REPL

Scanner Large up move: 85.7% (4.4x normal daily movement)

13h ago

Scanner Large up move: 85.7% (4.6x normal daily movement)

1d ago

News Replimune got another attempt at lead drug after White House intervention: WSJ

3d ago

Scanner Unusual buy pressure (4.5x avg, 65% up-volume, +76.1% / +3.56 intraday, above VWAP)

3d ago

SEC filing REPL Reports $12M Revenue, $0.05 EPS, Announces RP1 BLA Resubmission for Melanoma

3d ago

News Replimune Soars After FDA Reconsiders Denial of Skin Cancer Drug

4d ago

Insider trade Sale by Xynos Konstantinos (Chief Medical Officer)

12d ago

Insider trade Sale by Schwendenman Andrew (Chief Accounting Officer)

12d ago

Insider trade Sale by Sarchi Christopher (Chief Commercial Officer)

12d ago

Insider trade Sale by Astley-Sparke Philip

12d ago

Insider trade Sale by Patel Sushil (Chief Executive Officer)

12d ago

Insider trade Sale by Hill Emily Luisa (Chief Financial Officer)

12d ago

News Replimune (REPL) Gains on Positive Data From Melanoma Study

14d ago

News FDA head Makary defends drug application rejections amid criticism

27d ago

News Street sours on Replimune as stock hits all-time low on melanoma drug rejection

49d ago

News Replimune shares extend losses, tumble 56% after FDA rejects melanoma drug RP1

50d ago

News Replimune plans layoffs as FDA rejects cancer drug

51d ago

News Replimune’s Skin Cancer Drug Receives Second FDA Rejection

52d ago

News Replimune under pressure as FDA rejects lead asset again

52d ago

Insider trade Sale by Christopher Sarchi (Chief Commercial Officer)

56d ago

News Biotech firm stocks rise on FDA vaccine head’s exit

84d ago

Scanner Unusual buy pressure (4.3x avg, 63% up-volume, +11.2% / +0.82 intraday, above VWAP)

103d ago

News Replimune Group GAAP EPS of -$0.77 beats by $0.01

118d ago

SEC filing 8-K Filing

119d ago

News Replimune Highlights Acral Melanoma Data for RP1 plus Nivolumab at the ESMO Congress 2025

153d ago